{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:51:03Z","timestamp":1788187863581,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001348","name":"Agency of Science, Technology and Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"crossref"}]},{"name":"TRIDENT programme","award":["TP_25P6"],"award-info":[{"award-number":["TP_25P6"]}]},{"name":"Singapore National Medical Research Council COVID-19 Research Fund"},{"name":"Human Health and Potential Industry Alignment Fund pre-positioning grant","award":["(IAF-PP #H22J1a0050)"],"award-info":[{"award-number":["(IAF-PP #H22J1a0050)"]}]},{"name":"Nucleic Acid Therapeutics Initiative (NATi) grant","award":["(#H24J5a0038)"],"award-info":[{"award-number":["(#H24J5a0038)"]}]},{"DOI":"10.13039\/501100001459","name":"Ministry of Education - Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The development of mRNA vaccines has significantly advanced global health during the COVID-19 pandemic. However, translating effective vaccine doses from preclinical animal models to human clinical use remains poorly understood. In this study, we evaluated antibody responses and repertoire diversity across different BNT162b2 mRNA vaccine doses in mice, while comparing the results with human data through mathematical modeling. We observed that 1\u00a0\u03bcg BNT162b2 dose regimen induced a persistent antibody response and broad antibody repertoire for up to 16\u00a0weeks in mice. Conversely, 0.05\u00a0\u03bcg BNT162b2 dose regimen resulted in waning antibody responses and narrowed antibody repertoires over the same period, resembling responses observed in humans vaccinated with 30\u00a0\u03bcg BNT162b2 dose regimen. An empirical dose translation approach revealed a discrepancy in dose relevance between the 1\u00a0\u03bcg commonly used in the in vivo mice model and the 30\u00a0\u03bcg used for vaccination in human. Therefore, it is crucial to re-evaluate the appropriate mRNA vaccine dose for in vivo mice models to accurately reflect human responses.<\/jats:p>","DOI":"10.1038\/s41598-026-47820-z","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T16:08:56Z","timestamp":1777997336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Optimizing mouse models for mRNA vaccines: addressing dose translation challenges"],"prefix":"10.1038","volume":"16","author":[{"given":"Zi Wei","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Jie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Shan","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Ridwan","family":"Kabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Xiang","family":"Hor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiew Yee","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siti Nazihah Mohd","family":"Salleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve Zi Xian","family":"Ngoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"COVID-19 Cohort Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeline","family":"Rouers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Torres-Ruesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Soh Meoy","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline Chiew Yen","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Nguee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Neo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac Kai Jie","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajayanandan","family":"Yadunandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sooriya Kannan","family":"Selvam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarvis","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ng Kah","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sim Xin","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wong Wei","family":"Lun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Xinyi","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang Hui","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"NCID Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn Jin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng Kuang","family":"Soh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Qing","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan Jordon","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juwinda","family":"Ongko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshele Anak","family":"Libau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Theo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Ridzwan Bin","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiau Hui","family":"Diong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He Ping","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"COVID-19 Clinicians\u2019 Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surinder","family":"Pada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa Jin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond Luan Seng","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Somani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng Sing","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-I","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Lye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnaby E.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Zirui","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa F. P.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Renia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"47820_CR1","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577 (2020).","journal-title":"N. Engl. J. Med."},{"key":"47820_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416. https:\/\/doi.org\/10.1056\/NEJMoa2035389 (2021).","journal-title":"N. Engl. J. Med."},{"key":"47820_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111. https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1 (2021).","journal-title":"Lancet"},{"key":"47820_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect. Dis. 21, 181\u2013192. https:\/\/doi.org\/10.1016\/S1473-3099(20)30843-4 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"47820_CR5","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"PT Heath","year":"2021","unstructured":"Heath, P. T. et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med. 385, 1172\u20131183. https:\/\/doi.org\/10.1056\/NEJMoa2107659 (2021).","journal-title":"N. Engl. J. Med."},{"key":"47820_CR6","unstructured":"WHO. <https:\/\/covid19.who.int\/> (2024)."},{"key":"47820_CR7","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/eji.1830230749","volume":"23","author":"F Martinon","year":"1993","unstructured":"Martinon, F. et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol. 23, 1719\u20131722. https:\/\/doi.org\/10.1002\/eji.1830230749 (1993).","journal-title":"Eur. J. Immunol."},{"key":"47820_CR8","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/nbt.2436","volume":"30","author":"B Petsch","year":"2012","unstructured":"Petsch, B. et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against Influenza A virus infection. Nat. Biotechnol. 30, 1210\u20131216. https:\/\/doi.org\/10.1038\/nbt.2436 (2012).","journal-title":"Nat. Biotechnol."},{"key":"47820_CR9","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02482-20","author":"CJ Wollner","year":"2021","unstructured":"Wollner, C. J. et al. A dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses. J Virol https:\/\/doi.org\/10.1128\/JVI.02482-20 (2021).","journal-title":"J Virol"},{"key":"47820_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","volume":"592","author":"AB Vogel","year":"2021","unstructured":"Vogel, A. B. et al. BNT162b vaccines protect Rhesus macaques from SARS-CoV-2. Nature 592, 283\u2013289. https:\/\/doi.org\/10.1038\/s41586-021-03275-y (2021).","journal-title":"Nature"},{"key":"47820_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05482-0","volume":"9","author":"N Pardi","year":"2018","unstructured":"Pardi, N. et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat. Commun. 9, 3361. https:\/\/doi.org\/10.1038\/s41467-018-05482-0 (2018).","journal-title":"Nat. Commun."},{"key":"47820_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00324-5","volume":"6","author":"KV Kalnin","year":"2021","unstructured":"Kalnin, K. V. et al. Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. NPJ Vaccines 6, 61. https:\/\/doi.org\/10.1038\/s41541-021-00324-5 (2021).","journal-title":"NPJ Vaccines"},{"key":"47820_CR13","doi-asserted-by":"publisher","first-page":"1099991","DOI":"10.3389\/fimmu.2022.1099991","volume":"13","author":"S Bai","year":"2022","unstructured":"Bai, S. et al. A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice. Front. Immunol. 13, 1099991. https:\/\/doi.org\/10.3389\/fimmu.2022.1099991 (2022).","journal-title":"Front. Immunol."},{"key":"47820_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 7, 27\u201331. https:\/\/doi.org\/10.4103\/0976-0105.177703 (2016).","journal-title":"J. Basic Clin. Pharm."},{"key":"47820_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12010059","author":"I Pateev","year":"2023","unstructured":"Pateev, I., Seregina, K., Ivanov, R. & Reshetnikov, V. Biodistribution of RNA vaccines and of their products: Evidence from human and animal studies. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines12010059 (2023).","journal-title":"Biomedicines"},{"key":"47820_CR16","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439\u20132450. https:\/\/doi.org\/10.1056\/NEJMoa2027906 (2020).","journal-title":"N. Engl. J. Med."},{"key":"47820_CR17","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","volume":"390","author":"M Alberer","year":"2017","unstructured":"Alberer, M. et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: An open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390, 1511\u20131520. https:\/\/doi.org\/10.1016\/S0140-6736(17)31665-3 (2017).","journal-title":"Lancet"},{"key":"47820_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s12272-022-01381-7","volume":"45","author":"S Kwon","year":"2022","unstructured":"Kwon, S., Kwon, M., Im, S., Lee, K. & Lee, H. mRNA vaccines: The most recent clinical applications of synthetic mRNA. Arch. Pharm. Res. 45, 245\u2013262. https:\/\/doi.org\/10.1007\/s12272-022-01381-7 (2022).","journal-title":"Arch. Pharm. Res."},{"key":"47820_CR19","doi-asserted-by":"publisher","first-page":"27077","DOI":"10.1021\/acsnano.4c11652","volume":"18","author":"SJ Kent","year":"2024","unstructured":"Kent, S. J. et al. Blood distribution of SARS-CoV-2 lipid nanoparticle mRNA vaccine in humans. ACS Nano 18, 27077\u201327089. https:\/\/doi.org\/10.1021\/acsnano.4c11652 (2024).","journal-title":"ACS Nano"},{"key":"47820_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00742-7","volume":"8","author":"AJ Krauson","year":"2023","unstructured":"Krauson, A. J., Casimero, F. V. C., Siddiquee, Z. & Stone, J. R. Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients. NPJ Vaccines 8, 141. https:\/\/doi.org\/10.1038\/s41541-023-00742-7 (2023).","journal-title":"NPJ Vaccines"},{"key":"47820_CR21","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.chom.2024.11.007","volume":"32","author":"Z Rong","year":"2024","unstructured":"Rong, Z. et al. Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19. Cell Host Microbe. 32, 2112-2130 e2110. https:\/\/doi.org\/10.1016\/j.chom.2024.11.007 (2024).","journal-title":"Cell Host Microbe."},{"key":"47820_CR22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.121.056135","volume":"144","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt, B., Kamat, I. & Hotez, P. J. Myocarditis with COVID-19 mRNA vaccines. Circulation 144, 471\u2013484. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056135 (2021).","journal-title":"Circulation"},{"key":"47820_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9050511","author":"AH van Asbeck","year":"2021","unstructured":"van Asbeck, A. H. et al. Protein expression correlates linearly with mRNA dose over up to five orders of magnitude in vitro and in vivo. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines9050511 (2021).","journal-title":"Biomedicines"},{"key":"47820_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03765-3","volume":"5","author":"E Nanishi","year":"2022","unstructured":"Nanishi, E. et al. mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant. Commun. Biol. 5, 790. https:\/\/doi.org\/10.1038\/s42003-022-03765-3 (2022).","journal-title":"Commun. Biol."},{"key":"47820_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1031852","volume":"13","author":"YS Goh","year":"2022","unstructured":"Goh, Y. S. et al. Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals. Front. Immunol. 13, 1031852. https:\/\/doi.org\/10.3389\/fimmu.2022.1031852 (2022).","journal-title":"Front. Immunol."},{"key":"47820_CR26","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1126\/science.abn7591","volume":"375","author":"A Muik","year":"2022","unstructured":"Muik, A. et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science 375, 678\u2013680. https:\/\/doi.org\/10.1126\/science.abn7591 (2022).","journal-title":"Science"},{"key":"47820_CR27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114114","volume":"385","author":"H Chemaitelly","year":"2021","unstructured":"Chemaitelly, H. et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N. Engl. J. Med. 385, e83. https:\/\/doi.org\/10.1056\/NEJMoa2114114 (2021).","journal-title":"N. Engl. J. Med."},{"key":"47820_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32312-1","volume":"13","author":"L Renia","year":"2022","unstructured":"Renia, L. et al. Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. Nat. Commun. 13, 4615. https:\/\/doi.org\/10.1038\/s41467-022-32312-1 (2022).","journal-title":"Nat. Commun."},{"key":"47820_CR29","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature 586, 594\u2013599. https:\/\/doi.org\/10.1038\/s41586-020-2814-7 (2020).","journal-title":"Nature"},{"key":"47820_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/1348-0421.13043","volume":"67","author":"T Nakayama","year":"2023","unstructured":"Nakayama, T., Sawada, A. & Ito, T. Comparison of cytokine production in mice inoculated with messenger RNA vaccines BNT162b2 and mRNA-1273. Microbiol. Immunol. 67, 120\u2013128. https:\/\/doi.org\/10.1111\/1348-0421.13043 (2023).","journal-title":"Microbiol. Immunol."},{"key":"47820_CR31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2527869123","volume":"123","author":"M Wiatr","year":"2026","unstructured":"Wiatr, M. et al. Memory B cell development in response to mRNA SARS-CoV-2 and nanoparticle immunization in mice. Proc. Natl. Acad. Sci. U. S. A. 123, e2527869123. https:\/\/doi.org\/10.1073\/pnas.2527869123 (2026).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"47820_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41586-022-04778-y","volume":"607","author":"F Muecksch","year":"2022","unstructured":"Muecksch, F. et al. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature 607, 128\u2013134. https:\/\/doi.org\/10.1038\/s41586-022-04778-y (2022).","journal-title":"Nature"},{"key":"47820_CR33","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.immuni.2024.02.016","volume":"57","author":"MA Tortorici","year":"2024","unstructured":"Tortorici, M. A. et al. Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans. Immunity 57, 904-911 e904. https:\/\/doi.org\/10.1016\/j.immuni.2024.02.016 (2024).","journal-title":"Immunity"},{"key":"47820_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112511","volume":"28","author":"M Montiel-Ruiz","year":"2025","unstructured":"Montiel-Ruiz, M. et al. Immune imprinting and antibody profiles to SARS-CoV-2 in urban and rural Ghana. iScience 28, 112511. https:\/\/doi.org\/10.1016\/j.isci.2025.112511 (2025).","journal-title":"iScience"},{"key":"47820_CR35","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2024.02.017","volume":"57","author":"TS Johnston","year":"2024","unstructured":"Johnston, T. S. et al. Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants. Immunity 57, 912-925 e914. https:\/\/doi.org\/10.1016\/j.immuni.2024.02.017 (2024).","journal-title":"Immunity"},{"key":"47820_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-023-06753-7","volume":"625","author":"A Yisimayi","year":"2024","unstructured":"Yisimayi, A. et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature 625, 148\u2013156. https:\/\/doi.org\/10.1038\/s41586-023-06753-7 (2024).","journal-title":"Nature"},{"key":"47820_CR37","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41586-024-07539-1","volume":"630","author":"CY Liang","year":"2024","unstructured":"Liang, C. Y. et al. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Nature 630, 950\u2013960. https:\/\/doi.org\/10.1038\/s41586-024-07539-1 (2024).","journal-title":"Nature"},{"key":"47820_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0075-3","volume":"3","author":"SJ Rhodes","year":"2018","unstructured":"Rhodes, S. J. et al. Using vaccine immunostimulation\/immunodynamic modelling methods to inform vaccine dose decision-making. NPJ Vaccines 3, 36. https:\/\/doi.org\/10.1038\/s41541-018-0075-3 (2018).","journal-title":"NPJ Vaccines"},{"key":"47820_CR39","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567\u2013571. https:\/\/doi.org\/10.1038\/s41586-020-2622-0 (2020).","journal-title":"Nature"},{"key":"47820_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20653-8","volume":"12","author":"JH Tian","year":"2021","unstructured":"Tian, J. H. et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat. Commun. 12, 372. https:\/\/doi.org\/10.1038\/s41467-020-20653-8 (2021).","journal-title":"Nat. Commun."},{"key":"47820_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","volume":"369","author":"Q Gao","year":"2020","unstructured":"Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77\u201381. https:\/\/doi.org\/10.1126\/science.abc1932 (2020).","journal-title":"Science"},{"key":"47820_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2021.100671","volume":"2","author":"YS Goh","year":"2021","unstructured":"Goh, Y. S., Ng, L. F. P. & Renia, L. A flow cytometry-based assay for serological detection of anti-spike antibodies in COVID-19 patients. STAR Protoc. 2, 100671. https:\/\/doi.org\/10.1016\/j.xpro.2021.100671 (2021).","journal-title":"STAR Protoc."},{"key":"47820_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13030268","author":"W Tang","year":"2025","unstructured":"Tang, W. et al. SARS-CoV-2 mRNA vaccines induce cross-reactive antibodies to NL63 coronavirus but do not boost pre-existing immunity Anti-NL63 antibody responses. Vaccines https:\/\/doi.org\/10.3390\/vaccines13030268 (2025).","journal-title":"Vaccines"},{"key":"47820_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16638-2","volume":"11","author":"CM Poh","year":"2020","unstructured":"Poh, C. M. et al. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nat. Commun. 11, 2806. https:\/\/doi.org\/10.1038\/s41467-020-16638-2 (2020).","journal-title":"Nat. Commun."},{"key":"47820_CR45","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1128\/JVI.80.2.941-950.2006","volume":"80","author":"KM Lip","year":"2006","unstructured":"Lip, K. M. et al. Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus. J. Virol. 80, 941\u2013950. https:\/\/doi.org\/10.1128\/JVI.80.2.941-950.2006 (2006).","journal-title":"J. Virol."},{"key":"47820_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13040370","author":"M Hussain","year":"2025","unstructured":"Hussain, M. et al. Mind the age gap: Expanding the age window for mRNA vaccine testing in mice. Vaccines https:\/\/doi.org\/10.3390\/vaccines13040370 (2025).","journal-title":"Vaccines"},{"key":"47820_CR47","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1093\/infdis\/jiab592","volume":"225","author":"MA Brockman","year":"2022","unstructured":"Brockman, M. A. et al. Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults. J. Infect. Dis. 225, 1129\u20131140. https:\/\/doi.org\/10.1093\/infdis\/jiab592 (2022).","journal-title":"J. Infect. Dis."},{"key":"47820_CR48","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/s41422-020-00392-7","volume":"30","author":"J Lu","year":"2020","unstructured":"Lu, J. et al. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 30, 936\u2013939. https:\/\/doi.org\/10.1038\/s41422-020-00392-7 (2020).","journal-title":"Cell Res."},{"key":"47820_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.948335","volume":"13","author":"D Garcia-Dominguez","year":"2022","unstructured":"Garcia-Dominguez, D. et al. Altering the mRNA-1273 dosing interval impacts the kinetics, quality, and magnitude of immune responses in mice. Front. Immunol. 13, 948335. https:\/\/doi.org\/10.3389\/fimmu.2022.948335 (2022).","journal-title":"Front. Immunol."},{"key":"47820_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.07.047","volume":"42","author":"T Sanada","year":"2024","unstructured":"Sanada, T., Honda, T. & Kohara, M. Modeling of anti-spike IgG and neutralizing antibody waning after anti-SARS-CoV-2 mRNA vaccination. Vaccine 42, 126146. https:\/\/doi.org\/10.1016\/j.vaccine.2024.07.047 (2024).","journal-title":"Vaccine"},{"key":"47820_CR51","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1002\/jmv.27688","volume":"94","author":"KI Notarte","year":"2022","unstructured":"Notarte, K. I. et al. Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review. J. Med. Virol. 94, 2939\u20132961. https:\/\/doi.org\/10.1002\/jmv.27688 (2022).","journal-title":"J. Med. Virol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47820-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47820-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47820-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:28:05Z","timestamp":1783297685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47820-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["47820"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-47820-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An application to hold a patent for the SFB assay has been filed (Singapore patent #10202009679P): a method of detecting antibodies and related products). The authors declare no other competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20692"}}